Iveric Bio Inc Quick Ratio (ISEE) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Iveric Bio Inc   (NASDAQ: ISEE)

Iveric Bio Inc 's Quick Ratio

ISEE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2023, Quick Ratio fell to 15.24 above Iveric Bio Inc average.

Within Major Pharmaceutical Preparations industry 70 other companies have achieved higher Quick Ratio than Iveric Bio Inc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 66 to 250.

Explain Quick Ratio?
How much Cash & cash equivalents ISEE´s has?
What are ISEE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ISEE Quick Ratio (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1
Y / Y Current Liabilities Change 105.44 % 26.15 % 20.28 % 5.95 % -4.94 %
Y / Y Cash & cash equivalent Change 73.56 % 69.44 % 32.47 % 95.12 % 91.82 %
Quick Ratio MRQ 15.24 18.18 13.04 11.78 18.04
ISEE's Total Ranking # 250 # 66 # 302 # 310 # 192
Seq. Current Liabilities Change 10.64 % 44.73 % -7.14 % 38.16 % -32.06 %
Seq. Cash & cash equivalent Change -7.25 % 101.8 % 2.75 % -9.75 % -9.45 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 71
Healthcare Sector # 112
Overall Market # 250


Quick Ratio Statistics
High Average Low
40.13 13.99 1.87
(Mar 31 2014)   (Jun 30 2014)




Financial Statements
Iveric Bio Inc 's Current Liabilities $ 39 Millions Visit ISEE's Balance sheet
Iveric Bio Inc 's Cash & cash equivalent $ 600 Millions Visit ISEE's Balance sheet
Source of ISEE's Sales Visit ISEE's Sales by Geography


Cumulative Iveric Bio Inc 's Quick Ratio

ISEE's Quick Ratio for the trailling 12 Months

ISEE Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 35.79 % 12.8 % 8.5 % 4.52 % 20.47 %
Y / Y Cash & cash equivalent TTM Growth 66.41 % 68.6 % 71.68 % 64.01 % 30.23 %
Quick Ratio TTM 14.91 15.36 13.81 13.59 12.17
Total Ranking TTM # 3721 # 3506 # 66 # 292 # 3693
Seq. Current Liabilities TTM Growth 19.1 % 7.49 % 4.4 % 1.6 % -1.06 %
Seq. Cash & cash equivalent TTM Growth 15.65 % 19.49 % 6.13 % 13.47 % 17.17 %

Quick ratio ranking by company, industry and sector >> Back to ISEE Financial Strength Comparisons >> Go to Compare ISEE Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q1 2023 to $39.37 millions, cumulative Quick Ratio decreased to 14.91 above the ISEE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 563 other companies have achieved higher Quick Ratio than Iveric Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 3506 to 3721.

Explain Quick Ratio?
How much Cash & cash equivalents ISEE´s has?
What are ISEE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 564
Healthcare Sector # 1087
Within the Market # 3721


trailing twelve months Quick Ratio Statistics
High Average Low
20.16 11.24 5.39
(Jun 30 2015)   (Jun 30 2017)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Aprea Therapeutics Inc   37.52 $ 30.996  Millions$ 0.826  Millions
Prometheus Biosciences Inc   36.90 $ 713.670  Millions$ 19.340  Millions
Theseus Pharmaceuticals Inc   35.72 $ 236.634  Millions$ 6.624  Millions
Adc Therapeutics Sa  35.72 $ 310.547  Millions$ 8.694  Millions
Atossa Therapeutics Inc   35.32 $ 103.978  Millions$ 2.944  Millions
Design Therapeutics Inc   34.86 $ 315.392  Millions$ 9.047  Millions
Cyteir Therapeutics Inc   34.64 $ 137.204  Millions$ 3.961  Millions
Oramed Pharmaceuticals Inc  32.50 $ 153.734  Millions$ 4.730  Millions
Arca Biopharma Inc  32.27 $ 40.850  Millions$ 1.266  Millions
Dice Therapeutics Inc   32.16 $ 554.548  Millions$ 17.241  Millions
Astria Therapeutics Inc   31.97 $ 213.328  Millions$ 6.673  Millions
Altimmune inc   31.64 $ 165.729  Millions$ 5.238  Millions
Morphic Holding inc   31.25 $ 421.279  Millions$ 13.481  Millions
Ironwood Pharmaceuticals inc   31.05 $ 740.342  Millions$ 23.843  Millions
Neurogene Inc   30.87 $ 167.358  Millions$ 5.421  Millions
Nanoviricides inc   27.68 $ 9.651  Millions$ 0.349  Millions
Ars Pharmaceuticals Inc   26.89 $ 264.549  Millions$ 9.838  Millions
Acelyrin Inc   26.85 $ 289.194  Millions$ 10.770  Millions
Nuvalent Inc   26.47 $ 450.462  Millions$ 17.021  Millions
Edgewise Therapeutics inc   25.79 $ 327.952  Millions$ 12.715  Millions
Pliant Therapeutics Inc   24.93 $ 577.314  Millions$ 23.153  Millions
Terns Pharmaceuticals Inc   24.57 $ 297.526  Millions$ 12.109  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Cohbar Inc   24.20 $ 14.081  Millions$ 0.582  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Kura Oncology Inc   24.02 $ 405.900  Millions$ 16.901  Millions
Agios Pharmaceuticals Inc   23.75 $ 739.201  Millions$ 31.121  Millions
Disc Medicine Inc   23.69 $ 236.422  Millions$ 9.980  Millions
Rezolute Inc   23.49 $ 103.062  Millions$ 4.387  Millions
Xenon Pharmaceuticals Inc   23.43 $ 527.043  Millions$ 22.491  Millions

Date modified: 2026-09-08T15:10:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.